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Isolation of a Dengue Type 1 Virus from a
Soldier in West Africa (Côte d’Ivoire)
To the Editor: In Africa, recent reports of
epidemic or endemic dengue activity usually
come from the eastern part of the continent (1),
and the serotype most frequently identified is
dengue 2.
We report the isolation of a dengue 1 virus
strain from the blood of a young soldier living in
Abidjan, the capital of Côte d’Ivoire. This
20-year-old man arrived from France on October
19, 1998. On December 28, 1998, he consulted a
physician of his regiment because of headache,
diarrhea, and fever (40°C). The results of the
laboratory investigations were as follows:
platelets (193 109 /L), leukocytes (2.2109 /L); no
malaria was found. He was hospitalized for
possible arboviral infection, and treatment with
paracetamol was prescribed. On December 29, a
blood sample was collected; serum and buffy coat
were frozen at -20°C for further examination at
the Institute of Tropical Medicine of the Military
Health Services. On day 3, the patient’s
temperature dropped to 38°C, then rose to 39.5°C
on day 5. All symptoms were resolved on day 6.
On February 15, 1999, the frozen blood was
defrosted and the lysed buffy coat was
immediately cocultured with C6/36 cells. On day
6, a blind passage was made on the same cells
and on Vero. On day 12, no cytopathic effect was
observed, but a dengue 1 virus was identified by
indirect fluorescent antibody assay (2) with type-
specific monoclonal antibodies.  .  .  .  . This diagnosis
was confirmed by reverse transcription-poly-
merase chain reaction, with a technique slightly
modified from Lanciotti (3).
On the first blood specimen, the serologic
immunoglobulin (Ig)M assays (M antibody
capture enzyme-linked immunosorbent assay
[ELISA]) with our antigen screening panel were
negative (dengue, West Nile, Chikungunya, Rift
Valley fever). The IgG assay (ELISA) against
dengue antigen was also negative.
The patient returned to France in February
1999. A second blood sample was collected and
tested on April 7, 1999, 3 months after the
illness. The serologic assays were positive
against the dengue antigens at the following
dilutions of the serum: IgM: dengue 1: 1/120,000;
dengue 2: 1/40,000; dengue 3: 1/12,000; dengue 4:
1/25,000. IgG: dengue 1: 1/75,000; dengue 2: 1/
90,000; dengue 3: 1/60,000; dengue 4: 1/120,000.
This seroconversion allowed us to confirm
infection of this patient by a dengue virus.
The lack of similar reported cases or
epidemics among the local and expatriate
populations of Abidjan may indicate poor
transmission, recent introduction of the strain,
or low virulence of the virus, as previously
hypothesized for dengue in West Africa (4).
However, the serologic status of the human
population needs to be further investigated.
Characterization of the isolated viral strain
would be of interest for dengue epidemiology.
Complete sequencing of the viral RNA is in
progress in our laboratory.
Human infection with dengue virus has been
rarely reported and studied in West Africa, and
the epidemiology of serotype 1 is poorly
documented. During the past 35 years, the
Pasteur Institute of Dakar confirmed three
dengue 1 strains (two from humans in Senegal;
one from mosquitoes in Côte d’Ivoire), while
during the same period, more than 300 dengue 2
strains were studied, most from mosquitoes (5).
In the past 10 years, medical and entomologic
surveys showed circulation of dengue 2 virus in
Senegal (one isolate in the blood of a French
soldier) (6). However, during the 1970s, Nigerian
virologists demonstrated circulation of dengue 1
and 2 in their country: more than 50% of the
adults living in the savannah had neutralizing
antibodies (7). Of 148 blood samples of febrile
patients, three viral strains (yellow fever, dengue
1, and Zika) were isolated, all from children (8).
In Africa, outside the epidemics of yellow
fever, it is difficult to isolate arboviruses from
adult humans. Isolation is often more successful
from children or naive expatriates. Accordingly,
soldiers participating in international operations
constitute a very exposed population. During
recent operations in Somalia (1992-93), dengue
fever was an important cause of febrile illness
among U.S. troops (9). Thirty-nine dengue 2 and
three dengue 3 strains were isolated from 96
collected sera.
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Carbapenem-Hydrolyzing
Metallo-ß-Lactamase from a
Nosocomial Isolate of
Pseudomonas aeruginosa
in France
To the Editor: The carbapenems (meropenem
and imipenem), the ß-lactams with the broadest
spectrum, are stable to most ß-lactamases (1).
Therefore, they are often used as antibiotics of
last resort for treating nosocomial infections due
to gram-negative bacteria resistant to other
ß-lactams. Resistance to carbapenems and
susceptibility to other ß-lactams in Pseudomonas
aeruginosa is common as a result of reduced drug
accumulation or increased expression of pump
efflux (1).
Several extended-spectrum ß-lactamases
have been reported in P. aeruginosa, but only
two, IMP-1 and VIM-1, possess an extended
hydrolysis profile that includes carbapenems
(2-5). The chromosome-borne and plasmid-
mediated carbapenem-hydrolyzing ß-lactamase,
IMP-1, has been described in several gram-
negative rods, including P. aeruginosa, P. cepacia,
Alcaligenes xylosoxydans, and Enterobacteri-
aceae isolates in Japan (4,6). Recently, a
chromosome-borne carbapenem-hydrolyzing
ß-lactamase, VIM-1, was reported from a clinical
isolate of P .  aeruginosa in Italy (5), and
uncharacterized carbapenem-hydrolyzing
ß-lactamases have been reported in the United
Kingdom and Portugal (7,8). The weakly related
IMP-1 and VIM-1 (31.4% amino acid identity) are
both zinc-dependent (metallo-enzymes) and
confer resistance to all ß-lactams except
monobactams (3,5).
In 1996, a 39-year-old French woman was
hospitalized in Marseille for chronic myelog-
enous leukemia, pancytopenia, and allogeneic
bone marrow transplantation. After a 15-day
stay in the transplantation unit, fever developed
and imipenem and amikacin were administered.
Despite this treatment, the patient died of septic
shock syndrome 5 days later. Three-day-old
blood cultures grew a carbapenem-resis-
tant  P. aeruginosa isolate. This P. aeruginosa
COL-1 isolate was resistant to most ß-lactams,
including piperacillin/tazobactam, imipenem,
meropenem, ceftazidime, cefepime (minimum
inhibitory concentrations [MICs] of 128, 32, 16,
64, 32 mg/L, respectively), amikacin, tobramycin,
gentamicin, netilmicin, and ciprofloxacin; how-
ever, the isolate was susceptible to aztreonam
(MIC determination, genetic techniques and
ß-lactamase assays are described elsewhere [9]).
A sonicate of crude extract of P. aeruginosa
COL-1 culture showed strong imipenem and
meropenem hydrolysis activity (0.7 mU/mg and
1.9 mU/mg; reference P. aeruginosa strain <0.05
mU/mg) by UV spectrophotometry with 0.1 mM
of substrate, after incubation in 50 mM
phosphate buffer at 30°C. This activity was lost
when the enzyme extract was preincubated with
10 mM of edetic acid and was partially restored